pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,204 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1171Endpoints885BioPharma Dive340BioSpace304Fierce Biotech285onclive165raps104globenewswire health73
therapy area
allOncology7528Rare Disease1860Cardiology1714Immunology1473Hematology1317Vaccines1195Pulmonology
  • Opinion: What do medical students think about their education?
    “No one's pulling the pieces together”: a conversation with medical students about preventive care education.
    STAT · 4mo ago↗ source
  • Opinion: STAT readers on MAHA activists, perimenopause, and diversity in medical school
    “Unfortunately, the resources don't exist to take every flat-earther to the International Space Station to change their mind,” a STAT reader writes.
    STAT · 4mo ago↗ source
  • Arvinas’ ‘Protac’ breast cancer drug cleared by FDA
    Known as Veppanu, the drug is the first of its kind to get to market. But Arvinas and partner Pfizer are still searching for a new partner to sell it.
    BioPharma Dive · 4mo ago↗ source
← prev
page 84 of 89
next →
fda recalls67
fda medwatch60
fda press38
1145
Psychiatry & CNS866
Ophthalmology494
Pain478
Endocrinology & Metabolism468
Infectious Disease444
  • STAT+: Up and down the ladder: The latest comings and goings
    Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and…
    STAT · 4mo ago↗ source
  • Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal
    Summit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committee sided against an AstraZeneca breast c…
    BioPharma Dive · 4mo ago↗ source
  • Moderna sees revenue bump from international COVID vaccine sales
    The company is making up for a decline in U.S. vaccine sales with better results elsewhere, continuing a turnaround that’s vaulted its stock price in 2026.
    BioPharma Dive · 4mo ago↗ source
  • Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook
    Investors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by better-than-expected results for newer drugs like Leqembi and Skyclarys.
    BioPharma Dive · 4mo ago↗ source
  • STAT+: Axsome wins FDA nod for Alzheimer’s agitation
    Vinay Prasad's acting replacement, remembering genomics pioneer J. Craig Venter, and more biotech news from The Readout
    STAT · 4mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about obesity drugs and a compounding list, an AstraZeneca setback, and more
    The FDA proposed excluding the active ingredients in popular obesity and diabetes drugs from a list of substances that can be used for compounded versions
    STAT · 4mo ago↗ source
  • PFAS is still in some infant formula
    Casey Means out as surgeon general nominee, America's renewed fertility anxiety, and more health news
    STAT · 4mo ago↗ source
  • Opinion: America is worrying about fertility again. But it’s not really about families
    Where the state once worried about too many births, it now worries about too few.
    STAT · 4mo ago↗ source
  • STAT+: Her daughter Mila got a bespoke medicine. Now she’s starting a new biotech to make more
    Efforts to make customized medicines at scale have hit commercial and regulatory roadblocks. Julia Vintarello is trying again.
    STAT · 4mo ago↗ source
  • ‘Forever chemicals’ in baby formula? Scientists unpack FDA results
    FDA review confirmed overall safety of 16 brands of baby formula. In a STAT Q&A, experts unpack what low-level PFAS findings mean to worried moms.
    STAT · 4mo ago↗ source
  • Opinion: The psychedelic revolution is leaving behind people of color
    Psychedelics’ potential as a form of treatment is virtually unmatched. But their promise faces both scientific uncertainty and thorny political questions.
    STAT · 4mo ago↗ source
  • Two biotechs raise a combined $556M in latest spurt of IPOs
    Seaport Therapeutics and Hemab Therapeutics on Thursday became the latest drugmakers to debut on Wall Street, continuing a stretch of large IPOs this year that collectively raised almost $3.2 billion.
    BioPharma Dive · 4mo ago↗ source
  • STAT+: OxyContin maker Purdue Pharma set to dissolve after judge approves its criminal sentence
    At the hearing, the judge heard from mothers who lost sons to overdose, a teenager born into withdrawal, and people who spent years dealing with addiction treatment.
    STAT · 4mo ago↗ source
  • Remembering J. Craig Venter: a relentless scientist who changed biotech — and was all too easily misunderstood
    J. Craig Venter, the scientist whose relentless ambition helped turn genetics from an artisanal trade into an industrialized information machine, died at 79.
    STAT · 4mo ago↗ source
  • STAT+: Katherine Szarama named acting director of FDA’s vaccines and biologics center
    Katherine Szarama, who joined the FDA last year to serve as Vinay Prasad’s deputy, will now fill his shoes at CBER.
    STAT · 4mo ago↗ source
  • STAT+: In her own words: Surgeon general nominee Nicole Saphier expresses enthusiasm and caution for MAHA
    Examining the past statements and writings of Trump's third surgeon general nominee, Dr. Nicole Saphier, on vaccines, autism, peptides, diet and more.
    STAT · 4mo ago↗ source
  • STAT+: Hair-raising trial results, and Servier’s M&A wishlist
    Why are investors excited about hair loss drugs? Will AI make clinical trials run more smoothly? And more in "The Readout LOUD," STAT's weekly biotech podcast.
    STAT · 4mo ago↗ source
  • STAT+: As artificial intelligence shows off diagnostic chops, scientists reckon with the way forward
    On Thursday, researchers published in Science the results of a study that tested an OpenAI model on diagnostic and clinical reasoning tasks.
    STAT · 4mo ago↗ source
  • Trump drops Casey Means as surgeon general nominee, opts for radiologist Nicole Saphier
    Trump slammed Sen. Bill Cassidy for blocking his surgeon general pick, as he nominated a replacement.
    STAT · 4mo ago↗ source
  • Merck still sees ‘compelling’ outlook for Terns leukemia drug
    Despite updated study data that suggest Terns’ treatment may be less differentiated, company executives claimed Thursday that it still could be an important step forward in care.
    BioPharma Dive · 4mo ago↗ source
  • UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy
    News of the submission, which would be the first for UniQure’s closely watched treatment, comes as the therapy faces an uncertain future in the U.S.
    BioPharma Dive · 4mo ago↗ source
  • STAT+: FDA wants to exclude weight loss drugs from a compounding list
    FDA moves to remove semaglutide, tirzepatide, and liraglutide from its 503B compounding list, saying there's no shortage of GLP-1 drugs from Novo Nordisk and Eli Lilly.
    STAT · 4mo ago↗ source